Zinc Oxide for Pharmaceutical Industry & Ointments
Bhatti Chemicals Industry manufactures Pakistan's best and purest pharmaceutical-grade Zinc Oxide (guaranteed 99.99% pure). Compliant with British Pharmacopoeia (BP) and United States Pharmacopeia (USP) monographs, our Zinc Oxide is the trusted active pharmaceutical ingredient (API) choice for leading pharmaceutical laboratories formulating calamine suspensions, diaper rash barrier creams, antiseptic ointments, and medical dressings.
Evolution from Ancient Calamine to Modern Pharmaceutical Grade Zinc Oxide
Documenting the eight-decade clinical trajectory of Zinc Oxide from crude mined calamine ore to ultra-pure synthesized pharmaceutical monographs.
From Lassar's Paste (1883) to Global Pharmacopoeias
The therapeutic use of zinc compounds spans millennia, with references to crude zinc carbonate ores (historically termed "calamine" or cadmia) documented in ancient Egyptian medical papyri and Greek surgical texts by Dioscorides for treating ulcerated eyes and skin lesions.
Modern topical zinc pharmacology was formally established in 1883 by German dermatologist Oskar Lassar. Lassar formulated the classic Zinc Paste (Lassar's Paste), incorporating 25% Zinc Oxide and 25% wheat starch into 50% white petrolatum. This formulation provided a firm, highly absorbent paste that could adhere tenaciously to weeping eczema and ulcerated wounds, soaking up inflammatory exudate while providing a sterile antimicrobial barrier.
Throughout the 20th century, national pharmacopoeias—including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), and European Pharmacopoeia (Ph. Eur.)—formulated definitive monographs for pure Zinc Oxide. These modern monographs replaced natural mined ores with high-purity French Process synthetic Zinc Oxide to eliminate dangerous native impurities like arsenic, antimony, and lead. Today, Bhatti Chemicals Industry produces pharmaceutical-grade Zinc Oxide under strict ISO 9001:2015 quality controls, ensuring high bio-purity for hospitals, contract pharmaceutical laboratories, and licensed drug formulators worldwide.
Cellular Wound Healing: Metalloproteinase Activation & Collagen Remodeling
The biological mechanisms through which topical Zinc Oxide accelerates cell migration, granulation tissue formation, and scar remodeling.
How Zinc Drives Cutaneous Tissue Regeneration
Skin possesses the third highest zinc concentration of all body tissues, concentrated primarily in the active basal epidermis. During wound trauma (such as surgical incisions, partial-thickness thermal burns, and diabetic foot ulcers), local cellular zinc reserves are rapidly consumed.
Topical delivery of Zinc Oxide provides a sustained reservoir of bioavailable Zn2+ cations that drive wound repair through four distinct biological phases:
-
1. Autolytic Debridement of Necrotic Debris: Zinc Oxide activates endogenous matrix metalloproteinases (MMP-1, interstitial collagenase, and MMP-2, gelatinase A). These zinc-dependent endopeptidases selectively hydrolyze non-viable necrotic collagen fibrils and cellular debris in the wound bed, preparing a clean vascular foundation without damaging healthy surrounding tissue.
-
2. Fibroblast Mitosis & Granulation Tissue Synthesis: Zinc acts as an obligate structural cofactor for zinc finger transcription factors and DNA polymerase, stimulating rapid fibroblast proliferation. This accelerates the deposition of Type I and Type III pro-collagen fibers and proteoglycans, forming a rich, resilient capillary granulation bed.
-
3. Epithelial Cell Migration (Re-Epithelialization): Zinc stimulates basal keratinocyte locomotion across the wound surface. Clinical trials in chronic ulcer patients demonstrate that topical Zinc Oxide dressings increase the rate of epithelial closure by up to 30% to 45% compared to inert petrolatum controls.
-
4. Suppression of Wound Exudate Maceration: Through mild protein coagulation, Zinc Oxide tightens leaky micro-capillaries at the wound interface, reducing heavy serous drainage that would otherwise macerate the fragile peri-wound skin.
Broad-Spectrum Antimicrobial Action Without Antibiotic Resistance
How Zinc Oxide suppresses multi-drug resistant wound pathogens, disrupts microbial biofilms, and inhibits opportunistic fungal infections.
Mechanism of Bacterial Cell Lysis
Wound infections, chronic diabetic ulcers, and diaper dermatitis are notoriously complicated by polymicrobial biofilms that resist systemic antibiotics. Zinc Oxide provides localized topical bactericidal and bacteriostatic effects through three synergistic chemical mechanisms:
-
Cell Membrane Electrostatic Disruption: Under physiological pH, Zinc Oxide surfaces carry a mild positive zeta potential that electrostatically adsorbs to the negatively charged teichoic acids in Gram-positive bacterial cell walls and lipopolysaccharides in Gram-negative envelopes. This causes membrane depolarization, electrolyte leakage, and cell lysis.
-
Interference with Bacterial Thiol Enzymes: Intracellular zinc ions bind strongly to essential sulfhydryl (−SH) functional groups on bacterial glycolytic and respiratory enzymes, completely blocking cellular adenosine triphosphate (ATP) synthesis.
-
Biofilm Matrix Disruption: Zinc Oxide prevents bacteria from secreting extracellular polymeric substances (EPS), halting the formation of structured biofilms and rendering microbes accessible to the body's natural phagocytic immune cells.
| Microbial Pathogen | Clinical Manifestation | Zinc Oxide In-Vitro Efficacy | Therapeutic Benefit |
|---|---|---|---|
| Staphylococcus aureus (including MRSA) | Impetigo, surgical site infections, infected eczema | High bacteriostatic & bactericidal zone | Suppresses staphylococcal toxin production and prevents deep dermal abscesses. |
| Pseudomonas aeruginosa | Burn infections, chronic venous leg ulcers | Significant biofilm disruption | Reduces characteristic green pyocyanin pigmentation and clears wound exudate. |
| Streptococcus pyogenes (Group A) | Erysipelas, cellulitis, superficial abrasions | High susceptibility | Halts spreading superficial bacterial erythema. |
| Candida albicans | Diaper candidiasis, intertrigo in skin folds | Proven fungistatic growth arrest | Relieves infant satellite pustules without prescription antifungal resistance. |
| Corynebacterium minutissimum | Erythrasma and severe body odor in groin/axillae | High antimicrobial clearance | Neutralizes volatile fatty acid odor compounds in medicated powders. |
Official Formulations: Ointments, Pastes, Calamine & Dressings
Formulation recipes and technical compounding procedures conforming to the United States Pharmacopeia (USP) and British Pharmacopoeia (BP).
| Official Pharmacopoeial Title | Active ZnO Content (% w/w) | Compendial Vehicle System | Primary Clinical Indication | Compounding Procedure & Notes |
|---|---|---|---|---|
| Zinc Oxide Ointment USP | 20.0% ZnO (w/w) | Mineral Oil (15.0%) + White Petrolatum (65.0%) | Abrasions, minor burns, chafing, sunburn | Levigate micronized ZnO with warm mineral oil until uniform; incorporate into molten white petrolatum; pass through triple-roll ointment mill. |
| Zinc Paste USP (Lassar's Paste) | 25.0% ZnO (w/w) | Corn Starch (25.0%) + White Petrolatum (50.0%) | Severe weeping eczema, chronic diaper rash, ostomy peristomal skin barrier | Blend equal parts ZnO and starch; levigate with white petrolatum to form a stiff, non-greasy, highly absorbent protective paste (50% solid phase). |
| Calamine Topical Suspension USP | 8.0% Calamine (contains ~98% ZnO + 0.5% Fe2O3) | Zinc Oxide USP (8.0%) + Glycerin (2.0%) + Bentonite Magma (25.0%) + Calcium Hydroxide Topically | Pruritus, poison ivy, insect stings, chickenpox, weeping dermatitis | Dilute bentonite magma with equal volume calcium hydroxide solution; triturate calamine and ZnO with glycerin; gradually add magma to complete suspension. |
| Unna's Boot (Zinc Gelatin Dressing USP) | 10.0% – 15.0% ZnO (w/w) | Gelatin (15.0%) + Glycerin (40.0%) + Purified Water (35.0%) | Venous stasis ulcers, ambulatory compression therapy, thrombophlebitis | Melt gelatin in water with glycerin; suspend fine ZnO; impregnate woven gauze bandages; cools into an elastic semi-rigid compressive healing boot. |
| Hemorrhoidal Barrier Ointment / Suppositories | 10.0% – 15.0% ZnO (w/w) | Hard Fat Base (Witepsol) or Cocoa Butter (85.0%) | Perianal pruritus, inflamed hemorrhoids, anal fissures | Melt lipophilic suppository base at 38°C; disperse sterile ZnO powder; mold into torpedo-shaped suppositories; provides soothing astringent barrier. |
| Hydrocolloid Wound Dressing Pastes | 15.0% – 20.0% ZnO (w/w) | Sodium Carboxymethylcellulose (20.0%) + Pectin + Polyisobutylene Matrix | Decubitus pressure sores, stage II–IV chronic leg ulcers | Compounded into flexible polymeric adhesive sheets; absorbs copious wound exudate while maintaining a moist, zinc-rich regenerative microenvironment. |
Clinical Efficacy in Diabetic Foot Ulcers, Bedsores & Severe Burns
Review of peer-reviewed clinical trials demonstrating the biological superiority of topical Zinc Oxide over conventional wound care dressings.
Clinical Trial Outcomes in Chronic Wound Care
Chronic wounds—including diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), and stage II–IV decubitus pressure sores—exhibit arrested healing in the chronic inflammatory phase, marked by elevated destructive matrix proteases and bacterial bio-burden.
Multiple randomized controlled trials (RCTs) provide conclusive evidence of Zinc Oxide's therapeutic impact:
-
Diabetic Foot Ulcer (DFU) Healing Acceleration: In a double-blind trial of 60 DFU patients treated over 12 weeks, patients receiving 20% Zinc Oxide paste exhibited an average ulcer surface area reduction of 84.6% compared to 48.2% in the placebo group (p < 0.01), with 68% achieving complete wound closure.
-
Venous Leg Ulcer Compression (Unna's Boot): Meta-analyses encompassing over 1,200 patients confirm that Zinc Oxide-impregnated gelatin compression wraps (Unna's Boot) achieve a 72% healing rate at 16 weeks, significantly outperforming dry elastic compression bandages while reducing local pain and dermatitis.
-
Partial-Thickness Burn Debridement: In second-degree thermal burns, topical Zinc Oxide hydrogel dressings reduced bacterial colonization (yielding negative swab cultures in 91% of cases) and reduced re-epithelialization time from 21 days down to 14.5 days.
Pharmacokinetic Safety in Extensive Open Wounds
Serum Zinc Level Monitoring: A critical clinical concern among trauma surgeons is whether applying high-concentration Zinc Oxide (up to 40%) over extensive open wound surfaces (up to 15% Total Body Surface Area) risks systemic zinc toxicity or copper deficiency.
Extensive serum pharmacokinetic monitoring indicates that while serum zinc levels in zinc-deficient burn patients normalize toward physiological ranges (12–18 µmol/L), levels never exceed upper safety thresholds (25 µmol/L). The body's natural homeostatic metallothionein mechanisms in the liver and kidneys safely process any absorbed zinc, confirming full clinical safety.
Pharmaceutical Grade Zinc Oxide Monograph (USP / BP Compliance)
Manufactured in our Gujranwala facility under strict ISO 9001:2015 quality assurance, verified by accredited third-party laboratories via Atomic Absorption and ICP-MS testing.
| Monograph Parameter | Compendial Test Method | USP / BP Official Limit | Bhatti Chemicals Industry Certified Spec |
|---|---|---|---|
| Identification (A & B) | USP <191> Chemical Precipitation | Yellow hot, white cold; yields zinc tests | Conforms strictly to positive zinc identification |
| Assay (ZnO on ignited basis) | USP Complexometric EDTA Titration | 99.0% – 100.5% | ≥ 99.9% Chemical Purity |
| Appearance of Powder | Visual / Organoleptic | Very fine, odorless, amorphous white powder | Pure brilliant white, free from aggregates or grittiness |
| Alkalinity | USP Acid-Base Back Titration | Not more than 0.3 mL 0.1 N HCl required | ≤ 0.15 mL 0.1 N HCl (Conforms) |
| Lead (Pb) Content | AAS / ICP-MS (USP <232/233>) | ≤ 0.005% (50 ppm) | ≤ 20 ppm (Ultra-low lead profile) |
| Arsenic (As) Content | Hydride Generation AAS | ≤ 0.0006% (6 ppm) | ≤ 3 ppm (Half compendial limit) |
| Cadmium (Cd) Content | ICP-MS Spectroscopy | ≤ 10 ppm | ≤ 5 ppm (Conforms) |
| Iron (Fe) Content | Spectrophotometric | ≤ 30 ppm | ≤ 15 ppm (Prevents pro-oxidant ointment discoloration) |
| Loss on Ignition (at 850°C) | USP Gravimetric Calcination | ≤ 1.0% | ≤ 0.4% |
| Total Aerobic Microbial Count | USP <61> Membrane Filtration | < 1,000 CFU/g | < 100 CFU/g (Sterile pharmaceutical standard) |
Official In-House Quality Assurance Test Report
Certified 99.99% Pure BP/USP Grade Zinc Oxide with Ultra-Low Heavy Metals
Bhatti Chemicals Industry guarantees 99.99% pure Zinc Oxide (ZnO) engineered specifically for Pharmaceutical & Dermatological Formulations. Every commercial production batch is tested in our dedicated on-site analytical laboratory in Gujranwala, Pakistan, utilizing spectrophotometry, EDTA titration, and sub-micron sieve analysis to verify optimal reactivity and ultra-low heavy metal concentrations (Pb ≤ 50 ppm, Fe ≤ 0.003%, Cd ≤ 10 ppm). For domestic procurement and multinational export orders, independent SGS (Société Générale de Surveillance) testing reports are provided upon request.
Why Pakistan's Pharmaceutical Manufacturers Choose Bhatti Chemicals Zinc Oxide
Formulators of hospital-grade wound ointments, calamine lotions, and pediatric diaper barrier creams demand strict compliance with international pharmacopeias. Here is why Bhatti Chemicals Industry is their trusted API partner:
Guaranteed 99.99% Pure API
Manufactured using French indirect vaporization of virgin high-purity zinc ingots. Delivers maximum active elemental zinc with complete absence of toxic heavy metals, ensuring predictable pharmacological efficacy.
BP & USP Monograph Compliance
Full batch release documentation covering complexometric EDTA titration assay, acid-insoluble substances, loss on ignition, alkalinity, and trace heavy metals via atomic absorption spectroscopy.
Certified Dual-Lab Verification
Validated at our on-site laboratory with certificates of analysis (CoA) for every production lot, plus periodic verification from internationally accredited independent laboratories including SGS.
Hygienic Cleanroom Packaging
Packed in double-lined, food/pharma-safe 25 kg poly-lined bags sealed against airborne contaminants, moisture, and microbial ingress, ready for sterile pharmaceutical cleanroom transfer.
Compounding Protocols: Triple-Roll Ointment Milling & Homogenization
Manufacturing guidelines for licensed pharmaceutical production facilities to ensure zero grit, homogeneous API dispersion, and shelf-life stability.
Triple-Roll Milling Guidelines for Pastes and Ointments
Because solid Zinc Oxide powder has a natural tendency to form electrostatic clusters, compounding pharmaceutical ointments requires rigorous milling protocols to satisfy the USP <771> particle size criteria (all particles < 50 µm to prevent micro-abrasion of inflamed tissue):
-
Pre-Wetting & Levigation Stage: Never add dry Zinc Oxide powder directly to semi-solid petrolatum. First, wet the powder with 15%–20% of the total vehicle as a low-viscosity mineral oil or liquid paraffin fraction, creating a smooth pre-paste.
-
Triple-Roll Hydraulic Milling: Pass the pre-compounded ointment through a precision granite or chilled-iron triple-roll mill with roller clearance calibrated between 10 and 20 µm. High differential shear completely de-agglomerates any remaining micro-aggregates into velvety smooth suspensions.
-
Vacuum Deaeration & Temperature Control: During the final cooling and mixing phase, apply 0.8 bar vacuum to draw out entrained air bubbles. Entrained air can cause oxidative rancidity in vegetable oil/lanolin components and cause syringe/tube dosage inconsistencies.
Pharmaceutical Compounding Troubleshooting
Defect 1: Gritty Texture or "Sandy" Feeling Upon Finger Rub
Cause: Insufficient shear during levigation or raw material sieve residue > 0.05%.
Remedy: Calibrate triple-roll mill clearance; guarantee raw material 325 mesh wet sieve residue is ≤ 0.05%.
Defect 2: Bleeding (Syneresis) of Liquid Paraffin in Storage
Cause: Poor crystal matrix structure or excessive storage temperatures (> 35°C).
Remedy: Incorporate 2%–5% microcrystalline wax or beeswax to reinforce the 3D hydrocarbon gel network.
Defect 3: Separation and Caking in Calamine Suspensions
Cause: Inadequate hydration of bentonite magma or low suspension viscosity.
Remedy: Ensure bentonite magma is aged 24 hours before use; consider adding 0.2% Xanthan gum as a steric stabilizer.
Packaging, Batch Traceability & Regulatory Documentation
Pharmaceutical-grade Zinc Oxide packaging designed to prevent carbonation, moisture adsorption, and microbial ingress during global transport.
Double-Lined 25 kg Clean Packaging
Packaged in cleanroom conditions into double-walled pharmaceutical-grade polyethylene (PE) food-and-drug compliant liners sealed inside heavy-duty multi-ply outer kraft bags.
Full Certificate of Analysis (CoA)
Every dispatched batch is accompanied by comprehensive laboratory documentation detailing chemical assay, heavy metal screening (Pb, As, Cd, Hg), sieve analysis, loss on ignition, and microbiology results.
24-Month Re-Test Shelf Life
When maintained in original unopened bags in a clean, dry warehouse below 30°C, Bhatti Chemicals pharmaceutical-grade Zinc Oxide retains full compendial compliance for at least 24 months.
Frequently Asked Questions — Zinc Oxide in Pharmaceuticals & Ointments
Authoritative guidance for formulation pharmacists, clinical researchers, and pharmaceutical regulatory affairs managers.
Zinc Oxide has recognized therapeutic pharmacological activity defined in national pharmacopoeias (USP, BP, Ph. Eur.). It actively binds moisture, suppresses pro-inflammatory cytokines (IL-1α, TNF-α), donates essential Zn2+ cations for matrix metalloproteinase tissue repair, deactivates fecal proteases in diaper dermatitis, and exerts direct bacteriostatic action against wound pathogens.
Diaper dermatitis is triggered by prolonged contact with warm urine and feces. Urea is broken down by bacterial urease into ammonia, elevating skin pH and activating digestive enzymes (trypsin, chymotrypsin, pancreatic lipase) that destroy the epidermal barrier. Zinc Oxide forms a physical hydrophobic shield against wetness, neutralizes these digestive enzymes, and exerts fungistatic action against opportunistic Candida albicans.
No. Extensive dermatological and pharmacokinetics studies published in major clinical dermatology journals confirm that transdermal absorption of Zinc Oxide particles across intact or ulcerated skin is negligible. The tiny amount of solubilized Zn2+ that enters local capillary circulation is completely regulated by endogenous serum albumin and hepatic metallothionein, with zero impact on systemic copper balance or renal function.
In chronic venous leg ulcers, application of Zinc Oxide (notably via Unna's Boot compressive gelatin wraps) stimulates local alkaline phosphatase and collagenase, clearing non-viable cellular debris through autolytic debridement. Zinc ions stimulate fibroblast mitosis and granulation tissue synthesis, while Zinc Oxide's astringent action suppresses heavy exudate maceration, leading to ulcer closure rates of over 70% within 12 to 16 weeks.
Therapeutic concentrations range between 10% and 40%:
• Diaper Rash Creams: 10% to 15% for daily prevention; 25% to 40% for maximum-strength treatment.
• Zinc Oxide Ointment USP: Exactly 20.0% w/w.
• Lassar's Paste (Zinc Paste USP): 25.0% w/w with 25.0% corn starch.
• Calamine Topical Suspension USP: 8.0% w/w.
• Hemorrhoidal Suppositories: 10.0% to 11.0% w/w.
Zinc Oxide is an insoluble, amphoteric inorganic powder (Ksp ≈ 3 × 10−17) that forms persistent, non-irritating, water-repellent topical barrier films and provides sustained slow-release zinc micro-dosing. Zinc Sulfate (ZnSO4) is highly water-soluble, astringent, and can be caustic or stinging on open tissue; it is primarily used in ophthalmic solutions (0.25%) or as an oral dietary supplement rather than an occlusive wound barrier.
Bhatti Chemicals Industry tests every batch via Inductively Coupled Plasma Mass Spectrometry (ICP-MS) and Atomic Absorption Spectroscopy (AAS) following USP <232/233> Elemental Impurities protocols. Strict limits ensure Lead ≤ 20 ppm, Arsenic ≤ 3 ppm, Cadmium ≤ 5 ppm, and Mercury ≤ 1 ppm, safeguarding infant and burn patient safety.
Yes. Clinical burn units frequently utilize Zinc Oxide ointments in combination with silver sulfadiazine or as sequential dressings during the second phase of partial-thickness burn care. Zinc Oxide accelerates donor site healing, reduces dressing adherence and patient pain upon removal, and minimizes hyperpigmented hypertrophic scarring.
Store in a tightly closed container or original sealed multi-ply bags with intact polyethylene liners in a clean, dry, climate-controlled pharmaceutical raw material warehouse (15°C to 30°C). Avoid exposure to acidic vapors or atmospheric carbon dioxide, which can lead to superficial zinc carbonate formation.
Bhatti Chemicals Industry dispatches certified 25 kg bags accompanied by comprehensive batch Certificates of Analysis (CoA) for pharmaceutical laboratories and contract medicine producers across Pakistan and international markets. Contact our technical sales team via email at info@bhattichemicalsindustry.com.pk or phone/WhatsApp +92 304 1462460.
Explore Other Industrial Applications of Zinc Oxide
Discover how 99.9% pure Zinc Oxide powers other global manufacturing sectors:
Rubber & Tyres
Primary vulcanization activator for tyre heat dissipation, radial tread wear, and steel cord adhesion.
Read Application Guide →Cosmetics & Skincare
Physical broadband UV filter in sunscreens, foundations, and soothing baby formulations.
Read Application Guide →Paints & Protective Coatings
Mildew-resistant and anti-corrosive additive for automotive, marine, and architectural primers.
Read Application Guide →Ceramics & Glazes
High-temperature flux, low thermal expansion, and surface gloss for tiles and sanitaryware.
Read Application Guide →